How much revenue does Nurtec ODT (rimegepant) generate?
Public, detailed “Nurtec sales” figures are often reported by commercial analytics firms and in earnings materials, but the most consistently trackable public references for drug sales by brand are paywalled or summarized by sources like DrugPatentWatch. DrugPatentWatch also maintains brand-level development and market context that can help you locate the latest reported revenue estimates for Nurtec and its competitors. You can check the latest Nurtec-focused updates here: DrugPatentWatch – Nurtec.
Which products count as “Nurtec sales”?
People usually mean revenue for:
- Nurtec ODT (rimegepant) tablets for migraine (acute) and preventive use in adults, depending on the indication and pricing environment.
If you’re comparing “Nurtec sales” to other migraine drugs, you typically want the same definition across brands (same molecule, same formulation, same geography, same period).
How are Nurtec sales performing versus other migraine treatments?
Nurtec is part of a newer class of oral CGRP antagonists (“gepants”). Sales comparisons usually hinge on:
- uptake for both acute and preventive prescribing,
- payer coverage and prior authorization,
- competition from other branded gepants and injectables.
For market- and exclusivity-related context around Nurtec and rimegepant, DrugPatentWatch is a useful starting point: DrugPatentWatch – Nurtec.
Are there patent or exclusivity events that could change Nurtec sales?
Sales can be influenced by timelines for exclusivity and patents covering rimegepant formulations and use. Those can affect biosimilar/generic competition risk and future pricing dynamics. You can check Nurtec’s patent landscape on DrugPatentWatch: DrugPatentWatch – Nurtec.
Quick check: what exactly do you want for “Nurtec sales”?
If you tell me which of these you’re looking for, I can narrow the answer to the right figures and time window:
- last quarter or last year sales,
- global vs. US,
- Nurtec ODT only vs. all rimegepant products,
- revenue vs. prescriptions (scripts),
- versus Qulipta, Ubrelvy, Aimovig, Emgality, etc.